Abstract 1530P
Background
Pancreatic cancer (PC) is an aggressive malignancy with limited treatments and poor outcomes. Claudin 18.2 (CLDN18.2) antigen, a gastric-specific tightjunciton protein has been described frequently expressed in malignant gastrointestinal cancers including pancreatic cancer. FG-M108 is a human monoclonal antibody specifically targeting CLDN18.2 with optimal affinity and enhanced antibody-dependent cellularcytotoxicity (ADCC) activity.
Methods
with one cohort of an ongoing phase 1 study of FG-M108, eligible PC patients with positive CLDN18.2 expression (IHC 1+/2+/3+≥10%) were enrolled. The patients received FG-M108 (intravenous, 300 mg/m2, day1) plus gemcitabine (intravenous, 1000 mg/m2, day1,8) and nab-paclitaxel (intravenous, 125 mg/m2, day1,8) of each 3-week cycle. Primary endpoints included the incidence of adverse events (AEs) and preliminary clinical efficacy (ORR, DCR, DOR, PFS, OS, et al.).
Results
As of April 19, 2024, 35 patients received FG-M108 plus chemotherapy. Of 30 patients who received at least once tumor evaluation, ORR was 30.0% (9/30) and DCR was 100% (30/30), with one patient is still on treatment for 13.5 months. The most common M108-related AEs were nausea (54.3%), emesis (51.4%) and hypoalbuminemia (42.9%). Serious M108-related AEs occurred in 5 (5/35) participants. No M108-related grade 4 or 5 AEs and no treatment-related deaths were reported.
Conclusions
FG-M108 plus gemcitabine and nab-paclitaxel as first-line treatment in patients with Claudin-18.2+ advanced PC showed promising clinical efficacy with manageable safety. the safety and efficacy, especially PFS and OS will be further evaluated.
Clinical trial identification
CTR20210508.
Editorial acknowledgement
Legal entity responsible for the study
FutureGen Biopharm.
Funding
FutureGen BioPharm.
Disclosure
F. Liu, J. Gong, M. Zhang, X. Liang, J. Wang: Non-Financial Interests, Institutional, Local PI: FutureGen Biopharm. Y. Zhang, S. Zhang: Financial Interests, Institutional, Local PI: FutureGen Biopharm. Y. LI, Z. Jin, Y. Yang: Financial Interests, Institutional, Full or part-time Employment: FutureGen Biopharm. L. Shen: Non-Financial Interests, Institutional, Coordinating PI: FutureGen Biopharm.
Resources from the same session
1445P - Novel DNA methylation markers for early detection of cardia gastric adenocarcinoma and esophageal squamous cell carcinoma
Presenter: Zhiyuan Fan
Session: Poster session 18
Resources:
Abstract
1447P - Nal-IRI/LV5-FU versus paclitaxel as second-line therapy in patients with metastatic esophageal squamous cell carcinoma (OESIRI-PRODIGE 62): A FFCD multicenter, randomized, phase II study
Presenter: David Tougeron
Session: Poster session 18
1448P - IMHOTEP phase II trial of neoadjuvant pembrolizumab in dMMR/MSI localized cancers: Results of the digestive non-colorectal cancer cohorts
Presenter: Christelle de la Fouchardiere
Session: Poster session 18
1449P - Recurrent patient-reported outcome (PRO)-based symptomatic deterioration predicts progression-free survival (PFS): Results from RATIONALE-305
Presenter: Markus Moehler
Session: Poster session 18
1450P - Pembrolizumab and olaparib in advanced HER2 negative esophagogastric adenocarcinoma (EGA): Biomarker results of the phase II AIO IKF-038/POLESTAR trial
Presenter: Georg Martin Haag
Session: Poster session 18
1453P - A phase Ib study of AN0025 in combination with definitive chemoradiotherapy (dCRT) in unresectable locally advanced or locally recurrent esophageal cancer (EC)
Presenter: Nan Bi
Session: Poster session 18
1454P - An open label phase II study of lenvatinib with pembrolizumab and FLOT in the neoadjuvant and adjuvant treatment for patients with gastric and gastroesophageal junction adenocarcinoma (EPOC2001)
Presenter: Akihito Kawazoe
Session: Poster session 18